RemeGen (HKG:9995, SHA:688331) returned to profit in 2025, swinging year on year to a net profit attributable to owners of 708.5 million yuan, or 1.29 yuan per share, according to a Hong Kong filing disclosure on Saturday.
The biopharmaceutical company's Hong Kong shares slumped less than 6%, while Shanghai shares fell less than 3% during Monday's midday trade.
The attributable loss a year earlier was 1.47 billion yuan, or 2.73 yuan per share.
Total operating revenue jumped 89% to 3.25 billion yuan from 1.72 billion yuan in the previous year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments